MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
AbstractMelanoma-associated antigen 3 (MAGE-A3) expression is generally restricted to the placenta and germline cells of the testis, but it may also be expressed in sarcoma and other cancers and is associated with poor prognosis. Immunotherapy approaches targeting MAGE-A3 in other cancers have shown mixed results in the clinic, however, use of cancer testis antigens such as MAGE-A3 may have therapeutic value in the treatment of soft tissue sarcomas. Based on the recent success of anti-programmed death-1 (PD-1) therapy in undifferentiated pleomorphic sarcoma, we hypothesize that MAGE-A3-based immunotherapies may also provide benefits in this sarcoma type. We analyzed MAGE-A3 expression of sarcoma subtypes available in the Cancer Genome Atlas and Cancer Cell Line Encyclopedia and show that undifferentiated pleomorphic sarcoma/myxofibrosarcoma (UPS/MFS) expresses this potential target gene. We have identified high protein expression by tissue microarray of 106 UPS cores. We also found that high MAGE-A3 mRNA and protein expression is associated with worse overall survival in UPS/MFS. Furthermore, our results show no human leukocyte antigen (HLA) expression loss and relatively high lymphocyte infiltration by lymphocyte specific protein tyrosine kinase (LCK) marker expression. Based on these results, we propose targeting MAGE-A3 in UPS/MFS by immunotherapy techniques.
Share & Cite This Article
Conley, A.P.; Wang, W.-L.; Livingston, J.A.; Ravi, V.; Tsai, J.-W.; Ali, A.; Ingram, D.R.; Lowery, C.D.; Roland, C.L.; Somaiah, N.; Hwu, P.; Yee, C.; Subbiah, V.; Futreal, A.; Lazar, A.J.; Patel, S.; Roszik, J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers 2019, 11, 677.
Conley AP, Wang W-L, Livingston JA, Ravi V, Tsai J-W, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik J. MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers. 2019; 11(5):677.Chicago/Turabian Style
Conley, Anthony P.; Wang, Wei-Lien; Livingston, John A.; Ravi, Vinod; Tsai, Jen-Wei; Ali, Ali; Ingram, Davis R.; Lowery, Caitlin D.; Roland, Christina L.; Somaiah, Neeta; Hwu, Patrick; Yee, Cassian; Subbiah, Vivek; Futreal, Andrew; Lazar, Alexander J.; Patel, Shreyaskumar; Roszik, Jason. 2019. "MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma." Cancers 11, no. 5: 677.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.